WallStreetZenWallStreetZen

NASDAQ: MRNS
Marinus Pharmaceuticals Inc Stock

$1.41-0.03 (-2.08%)
Updated Apr 18, 2024
MRNS Price
$1.41
Fair Value Price
N/A
Market Cap
$77.05M
52 Week Low
$1.11
52 Week High
$11.26
P/E
-0.54x
P/B
4.6x
P/S
18.85x
PEG
N/A
Dividend Yield
N/A
Revenue
$30.99M
Earnings
-$141.41M
Gross Margin
93.8%
Operating Margin
-406.75%
Profit Margin
-456.3%
Debt to Equity
9.19
Operating Cash Flow
-$118M
Beta
1.35
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A

MRNS Overview

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MRNS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

MRNS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MRNS is good value based on its book value relative to its share price (4.6x), compared to the US Biotechnology industry average (5.76x)
P/B vs Industry Valuation
MRNS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MRNS due diligence checks available for Premium users.

Be the first to know about important MRNS news, forecast changes, insider trades & much more!

MRNS News

Valuation

MRNS fair value

Fair Value of MRNS stock based on Discounted Cash Flow (DCF)
Price
$1.41
Fair Value
-$4.58
Undervalued by
130.80%
MRNS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

MRNS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.54x
Industry
15.68x
Market
41.33x

MRNS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.6x
Industry
5.76x
MRNS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

MRNS's financial health

Profit margin

Revenue
$7.2M
Net Income
-$41.8M
Profit Margin
-580.9%
MRNS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MRNS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$170.9M
Liabilities
$154.1M
Debt to equity
9.19
MRNS's short-term assets ($165.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MRNS's short-term assets ($165.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MRNS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MRNS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$27.0M
Investing
$6.5M
Financing
$661.0k
MRNS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

MRNS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
MRNS$77.05M-2.08%-0.54x4.60x
AFMD$77.20M-3.06%-0.66x1.23x
CUE$76.86M-3.07%-1.42x2.07x
ONCY$76.66M-0.96%-3.42x3.78x
BTAI$77.97M-1.54%-0.41x-1.38x

Marinus Pharmaceuticals Stock FAQ

What is Marinus Pharmaceuticals's quote symbol?

(NASDAQ: MRNS) Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol MRNS. Marinus Pharmaceuticals stock quotes can also be displayed as NASDAQ: MRNS.

If you're new to stock investing, here's how to buy Marinus Pharmaceuticals stock.

What is the 52 week high and low for Marinus Pharmaceuticals (NASDAQ: MRNS)?

(NASDAQ: MRNS) Marinus Pharmaceuticals's 52-week high was $11.26, and its 52-week low was $1.11. It is currently -87.48% from its 52-week high and 27.03% from its 52-week low.

How much is Marinus Pharmaceuticals stock worth today?

(NASDAQ: MRNS) Marinus Pharmaceuticals currently has 54,642,580 outstanding shares. With Marinus Pharmaceuticals stock trading at $1.41 per share, the total value of Marinus Pharmaceuticals stock (market capitalization) is $77.05M.

Marinus Pharmaceuticals stock was originally listed at a price of $32.00 in Jul 31, 2014. If you had invested in Marinus Pharmaceuticals stock at $32.00, your return over the last 9 years would have been -95.59%, for an annualized return of -29.31% (not including any dividends or dividend reinvestments).

How much is Marinus Pharmaceuticals's stock price per share?

(NASDAQ: MRNS) Marinus Pharmaceuticals stock price per share is $1.41 today (as of Apr 18, 2024).

What is Marinus Pharmaceuticals's Market Cap?

(NASDAQ: MRNS) Marinus Pharmaceuticals's market cap is $77.05M, as of Apr 19, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Marinus Pharmaceuticals's market cap is calculated by multiplying MRNS's current stock price of $1.41 by MRNS's total outstanding shares of 54,642,580.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.